Camurus AB News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

10.10.18	Camurus to Present at Jefferies 2018 London Healthcare Conference (PR Newswire)
21.09.18	CHMP Recommends Approval of Buvidal® (CAM2038) for the Treatment of Opioid Dependence (PR Newswire)
21.09.18	CHMP Recommends Approval of Buvidal® (CAM2038) for the Treatment of Opioid Dependence (PR Newswire)
18.09.18	Camurus Announces Positive Topline Phase 3 Results for CAM2038 in Opioid Experienced Patients With Chronic Low-back Pain (PR Newswire)
18.09.18	Camurus Announces Positive Topline Phase 3 Results for CAM2038 in Opioid Experienced Patients With Chronic Low-back Pain (PR Newswire)
16.07.18	Camurus Announces PDUFA Date for CAM2038 for the Treatment of Opioid use Disorder (PR Newswire)
16.07.18	Camurus Announces PDUFA Date for CAM2038 for the Treatment of Opioid use Disorder (PR Newswire)
02.05.17	Camurus and Braeburn Pharmaceuticals Announce Positive Top-line Results from Phase 3 Safety Study of CAM2038 (PR Newswire)
02.05.17	Camurus and Braeburn Pharmaceuticals Announce Positive Top-line Results from Phase 3 Safety Study of CAM2038 (PR Newswire)
14.11.16	Camurus AB: Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Phase 3 Results for Long-acting Buprenorphine for Treatment of Opioid Addiction (Businesswire)
08.11.16	Camurus AB: Interim Report January-September 2016 (Businesswire)
28.10.16	Camurus AB: Nomination Committee Appointed in Respect of AGM 2017 in Camurus (Businesswire)
24.10.16	Camurus AB: Braeburn Pharmaceuticals and Camurus Expand Collaboration and License Agreement to Include New Combination Product for Pain and Nausea (Businesswire)
14.07.16	Camurus AB: Interim Report January-June 2016 (Businesswire)
17.05.16	Camurus AB: Camurus Interim Report January-March 2016 (Businesswire)
11.05.16	Camurus AB: Braeburn Pharmaceuticals and Camurus Announce Positive Results from Phase 2 Opioid Challenge Study with CAM2038 in Subjects with Opioid Use Disorder (Businesswire)
03.05.16	Camurus AB: Resolutions at the Annual General Meeting 2016 in Camurus (Businesswire)
21.04.16	Camurus AB: Distribution Agreement Signed with R-PHARM US for episil® (Businesswire)
05.04.16	Braeburn Pharmaceuticals and Camurus announce Enrollment goals reached in two pivotal Phase 3 Trials of CAM2038 for treatment of opioid dependence (Businesswire)
30.03.16	Camurus AB: Camurus Annual Report for 2015 released (Businesswire)
30.03.16	Notice of Annual General Meeting 2016 and Proposal for New Incentive Program in Camurus AB (publ) (Businesswire)
22.02.16	Camurus AB: Braeburn and Camurus Announce Initiation of a Phase 2 Study in Opioid Dependent Patients with Moderate to Severe Chronic Pain (Businesswire)
17.02.16	Camurus AB: Full Year Report January-December 2015 (Businesswire)
04.02.16	Camurus AB: Nomination Committee Appointed in Respect of AGM 2016 in Camurus (Businesswire)
07.01.16	Camurus AB: Change in the Number of Shares and Votes in Camurus (Businesswire)
05.01.16	Camurus AB: Rhythm and Camurus Announce License Agreement for Extended Release FluidCrystal Setmelanotide (Businesswire)
30.12.15	Camurus AB: Braeburn Pharmaceuticals and Camurus Enroll First Patient in a Phase 3 Efficacy Trial of Long-Acting Treatment for Opioid Dependence (Businesswire)
15.12.15	Camurus AB: Braeburn Pharmaceuticals and Camurus Announces Start of Phase 3 Trial of Long-Acting Buprenorphine Treatments for Opioid Dependence (Businesswire)
14.12.15	Camurus AB: Camurus Appoints Chief Commercial Officer (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’271.00	0.32 %	K V
ABB	52.04	0.31 %	K V
Holcim	89.06	0.23 %	K V
Alcon	76.32	0.00 %	K V
Sonova Hldg	297.30	0.00 %	K V
Givaudan	4’029.00	-0.79 %	K V
Swisscom	503.00	-0.79 %	K V
Swiss Re	130.50	-1.10 %	K V
Nestle	74.08	-1.52 %	K V
Sika	222.30	-1.72 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Camurus AB

Aktien Top/Flop

Meistgelesene Nachrichten